Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
1.900
+0.120 (6.74%)
At close: Oct 9, 2025, 4:00 PM EDT
1.900
0.00 (0.00%)
After-hours: Oct 9, 2025, 4:00 PM EDT
Senti Biosciences Employees
Senti Biosciences had 34 employees as of December 31, 2024. The number of employees decreased by 14 or -29.17% compared to the previous year.
Employees
34
Change (1Y)
-14
Growth (1Y)
-29.17%
Revenue / Employee
n/a
Profits / Employee
-$1,789,500
Market Cap
49.44M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 34 | -14 | -29.17% |
Dec 31, 2023 | 48 | -74 | -60.66% |
Dec 31, 2022 | 122 | 33 | 37.08% |
Dec 31, 2021 | 89 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SNTI News
- 3 days ago - Senti Bio to Present at BioJapan - GlobeNewsWire
- 21 days ago - Senti Bio to Present at the MedInvest Biotech & Pharma Conference - GlobeNewsWire
- 5 weeks ago - Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 2 months ago - Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - GlobeNewsWire
- 2 months ago - Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire